View in EDS

2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures.

Saved in:
Bibliographic Details
Title: 2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures.
Authors: Williams MS, Levine GN, Kalra D; ACC/AHA Joint Committee on Performance Measures., Agarwala A, Baptiste D; Preventive Cardiovascular Nurses Association representative., Cigarroa JE, Diekemper RL; AHA/ACC joint staff representative., Foster MV, Gulati M; American Society for Preventive Cardiology representative., Henry TD; Society for Cardiovascular Angiography and Interventions representative., Itchhaporia D, Lawton JS, Newby LK; 2023 AHA/ACC Chronic Coronary Disease Guideline liaison., Rogers KC; American College of Clinical Pharmacy representative., Soni K, Tamis-Holland JE
Source: Circulation. Cardiovascular quality and outcomes [Circ Cardiovasc Qual Outcomes] 2025 Jun; Vol. 18 (6), pp. e000140. Date of Electronic Publication: 2025 Apr 30.
Publication Type: Journal Article; Practice Guideline
Language: English
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101489148 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-7705 (Electronic) Linking ISSN: 19417713 NLM ISO Abbreviation: Circ Cardiovasc Qual Outcomes Subsets: MEDLINE
Imprint Name(s): Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins
MeSH Terms: Cardiology*/standards , Coronary Disease*/therapy , Coronary Disease*/diagnosis , Coronary Disease*/epidemiology , Evidence-Based Medicine*/standards , Outcome and Process Assessment, Health Care*/standards , Quality Improvement*/standards , Quality Indicators, Health Care*/standards, Humans ; American Heart Association ; Chronic Disease ; Consensus ; Risk Factors ; Treatment Outcome ; United States/epidemiology
Abstract: Chronic coronary disease (CCD) is the leading cause of death in the United States. There is an ongoing imperative to disseminate evidence-based and patient-centered care recommendations that further align the management of patients with CCD to updated evidence-based guidelines. The writing committee developed a comprehensive CCD measure set comprising 10 performance measures and 3 quality measures, the focus of which is to include practical steps to specifically advance care in the CCD population. The measure set begins with an assessment of tobacco use and evidence-based cessation interventions. Also included are topics such as antiplatelet therapy, lipid assessment and low-density lipoprotein cholesterol goals, and guideline-directed management and therapy for hypertension and reduced left ventricular dysfunction in patients with CCD. The measure set concludes with an emphasis on the importance of cardiac rehabilitation referral and patient education, including symptom management and lifestyle modification.
Comments: Erratum in: Circ Cardiovasc Qual Outcomes. 2025 Jul;18(7):e000141. doi: 10.1161/HCQ.0000000000000141.. (PMID: 40663623)
Contributed Indexing: Keywords: AHA Scientific Statements; chronic coronary disease; performance measures; quality indicators; quality measures
Entry Date(s): Date Created: 20250430 Date Completed: 20250617 Latest Revision: 20250715
Update Code: 20250717
DOI: 10.1161/HCQ.0000000000000140
PMID: 40305583
Database: MEDLINE
Description
Abstract:Chronic coronary disease (CCD) is the leading cause of death in the United States. There is an ongoing imperative to disseminate evidence-based and patient-centered care recommendations that further align the management of patients with CCD to updated evidence-based guidelines. The writing committee developed a comprehensive CCD measure set comprising 10 performance measures and 3 quality measures, the focus of which is to include practical steps to specifically advance care in the CCD population. The measure set begins with an assessment of tobacco use and evidence-based cessation interventions. Also included are topics such as antiplatelet therapy, lipid assessment and low-density lipoprotein cholesterol goals, and guideline-directed management and therapy for hypertension and reduced left ventricular dysfunction in patients with CCD. The measure set concludes with an emphasis on the importance of cardiac rehabilitation referral and patient education, including symptom management and lifestyle modification.
ISSN:1941-7705
DOI:10.1161/HCQ.0000000000000140